24/04/2014 05:07:13 Free Membership Login

Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
03/14/20141:00PMGLOBENymox Reports 2013 Financial Results
HASBROUCK HEIGHTS, N.J., March 14, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the... More...>>
02/05/20142:00PMGLOBENymox Announces Appointment of Andre Monette
HASBROUCK HEIGHTS, N.J., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive... More...>>
01/28/201411:30AMGLOBENymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
HASBROUCK HEIGHTS, N.J., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase... More...>>
01/13/201410:00AMGLOBENymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
HASBROUCK HEIGHTS, N.J., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line... More...>>
11/14/201310:15AMGLOBENymox Reports Third Quarter 2013 Financial Results
HASBROUCK HEIGHTS, N.J., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2013. Nymox reported a net loss of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September... More...>>
11/11/201311:45AMGLOBENymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH... More...>>
09/26/20139:45AMGLOBENymox Prostate Cancer Drug Treatment Trial Nears Completion
HASBROUCK HEIGHTS, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that enrollment in the company's NX03-0040 US Phase 2 clinical trial of NX-1207 for localized prostate cancer is nearing completion with over 80% patients now enrolled. Based on current screening and... More...>>
08/22/201310:15AMGLOBENymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial
HASBROUCK HEIGHTS, N.J., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee periodic review of safety data for the Company's NX02-0018 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational... More...>>
08/14/201310:00AMGLOBENymox Reports Second Quarter 2013 Financial Results
HASBROUCK HEIGHTS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the second quarter of 2013. Nymox reported net losses of $1,477,389, or $0.04 per share, for the quarter and $2,571,295, or $0.08 per share, for the six months ended June 30... More...>>
07/11/201312:45PMGLOBENymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial
HASBROUCK HEIGHTS, N.J., July 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee review of ongoing safety data for the Company's NX02-0017 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational... More...>>
06/05/20139:45AMGLOBENymox to Present at Jefferies 2013 Healthcare Conference in New York City on June 6
HASBROUCK HEIGHTS, N.J., June 5, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox, will be providing a corporate summary and presentation regarding the Company's ongoing clinical program for NX-1207 at the... More...>>
05/15/20139:45AMGLOBENymox Reports First Quarter 2013 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2013. Nymox reported a net loss of $1,093,906, or $0.03 per share for the quarter ended March 31, 2013, compared to $1,846,974, or $0.06 per share for the... More...>>
05/06/20139:00AMGLOBENymox Reports on Symposium and Panel Discussion on NX-1207 at American Urological Association Annual Meeting
HASBROUCK HEIGHTS, N.J., May 6, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation on NX-1207 drug studies at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Diego, CA between 3:00 and 4:00... More...>>
05/03/201311:47AMGLOBENymox Announces Completion of Patient Enrollment in Final Pivotal U.S. Phase 3 BPH Study
HASBROUCK HEIGHTS, N.J., May 3, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today completion of patient enrollment in the Company's final pivotal U.S. Phase 3 NX02-0018 Study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3... More...>>
04/30/201311:02AMGLOBENymox NX-1207 Symposium May 5 in San Diego at Annual Meeting of American Urological Association at San Diego Convention Center
HASBROUCK HEIGHTS, N.J., April 30, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce further information about the upcoming Symposium on NX-1207 to be held on May 5 at 3 p.m. in San Diego at the Annual Meeting of the American Urological Association at the San Diego Convention... More...>>
04/23/201312:00PMGLOBENymox Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the first patient has been enrolled in the Company's Study NX02-0022. The NX02-0022 Study is designed as an open label study of the safety and efficacy of NX-1207 reinjection for the treatment... More...>>
04/16/201310:32AMGLOBENew Study Supports Favorable Sexual Function Profile for Nymox's NX-1207 for Prostate Enlargement
HASBROUCK HEIGHTS, N.J., April 16, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings which have demonstrated that the Company's NX-1207 Phase 3 treatment for benign prostatic hyperplasia (BPH or prostatic enlargement) has no detectable effect on key male... More...>>
04/11/20139:50AMGLOBENymox NX-1207 BPH and Prostate Cancer Symposium at American Urological Association Annual Meeting May 5 in San Diego
HASBROUCK HEIGHTS, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for... More...>>
04/02/20135:00PMGLOBEPress Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical Corporation
MONTREAL, April 2, 2013 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by the early warning requirements of applicable Canadian securities laws. Paul Averback MD of 9900 Cavendish Blvd. Suite 306, St-Laurent, Quebec, announces today that he has sold in a private transaction for financial planning... More...>>
03/27/201311:00AMGLOBENymox's NicAlert(TM) Has Achieved Widespread Acceptance in Tobacco-Related Research Studies
HASBROUCK HEIGHTS, N.J., March 27, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today that the Company's FDA Cleared NicAlertâ„¢ product continues to achieve widespread acceptance around the world as an important tool in tobacco-related research studies and programs in a broad range... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nymx140424 05:07